Overview

Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE.

Status:
Completed

Trial end date:
2015-08-01

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to evaluate the safety, tolerability, and efficacy of 4 weeks intravenous treatment with Cpn10 in subjects with mild to moderate active SLE.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Invion, Inc.

Treatments:

Early pregnancy factor